The increase in the demand for laboratory and analysis equipment in India is expected to be reflected at this year?s Analytica Anacon India: The organizers have reported that they are expecting around 140 exhibitors from 13 countries.
The increase in the demand for laboratory and analysis equipment in India is expected to be reflected at this year’s Analytica Anacon India: The organizers have reported that they are expecting around 140 exhibitors from 13 countries. The trade fair will take place between 12–14 October 2011 at the Bombay Exhibition Centre, Mumbai, India.
“New requirements in the sector for food safety and the latest developments in pharmaceuticals production have led to high growth rates on the market for laboratory and analysis equipment. And thanks to large investments, among other things, this growth is expected to continue in the future,” says Susanne Grödl, exhibition director for Analytica in Munich. “As the country with one of the largest numbers of food manufacturers in the world — and as an export nation — India is subject to international guidelines and quality requirements. To ensure compliance with growing requirements, the Indian government has decided to increase the number of laboratories from 72 to between 250 and 300 facilities. That alone will increase volume on the market for analysis and biotechnology instruments by more than one billion US dollars. Above all, more efficient analysis techniques and new methods for the improved recognition of possible dioxin or pesticide residues in foods, which would make more reliable analysis results possible, are in the greatest demand.”
According to the organizers, Analytica Anacon India will give users who work in laboratories an opportunity to gather information about the latest products and innovations that feature these interdisciplinary technologies. Almost 140 domestic and international companies including industry leaders such as Agilent, BRAND, Dionex, Metrohm, Phenomenex, RFCL, Sigma Aldrich and Waters are expected to participate in this year’s fair.
The Analytica Anacon Conference also examines the latest trends on the Indian market. Topics include the life-sciences sector, the future of personalized genomes in medicine and food safety as well as hot topics in the pharma industry, including the use of bioanalysis in the pharmaceuticals sector.
For a list of exhibitors visit http://www.analyticaindia.com/en/Home/exhibitors/Exhibitor_list
The complete conference agenda is available online athttp://www.analyticaindia.com/en/Home/conference-program/analytica-anacon-india-conference
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.